Compare Sanofi SA (SNY) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sanofi SA vs TransMedics Group Inc — how do they compare? Sanofi SA trades at $44.05 (market cap $104.83B), while TransMedics Group Inc trades at $74.3 (market cap $2.54B). The key difference: Sanofi SA is far larger — about 41.3× TransMedics Group Inc's market cap, and Sanofi SA pays a 5.5% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.
| SNY | TMDX | |
|---|---|---|
Market Cap | $104.83B | $2.54B |
Sector | Health | Technology |
52-Week High | $52.34 | $150.42 |
52-Week Low | $41.33 | $61.99 |
Enterprise Value | $121.32B | $2.94B |
Dividend Yield | 5.5% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
